Trial Outcomes & Findings for Trial of Rituximab for Graves' Ophthalmopathy (NCT NCT00595335)
NCT ID: NCT00595335
Last Updated: 2016-01-01
Results Overview
The clinical activity score (CAS), for Grave's ophthalmopathy has become a widely accepted tool to assess disease activity and help decide the management of the condition. The CAS, which is based on classical signs of inflammation (pain, redness, and swelling), consists of 7 equally weighted items. The total CAS (as used in this study) may range from 0 to 7. The higher the CAS, the greater degree of inflammation is present. A drop in CAS of 2 or more points suggests an improvement in the inflammatory components of the disease. A CAS ≥3 implies active disease.
COMPLETED
PHASE2/PHASE3
25 participants
baseline, 6 months after the first infusion
2016-01-01
Participant Flow
Participant milestones
| Measure |
Rituximab
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Baseline to Six Months
STARTED
|
13
|
12
|
|
Baseline to Six Months
COMPLETED
|
11
|
10
|
|
Baseline to Six Months
NOT COMPLETED
|
2
|
2
|
|
Six Months to Twelve Months
STARTED
|
11
|
10
|
|
Six Months to Twelve Months
COMPLETED
|
10
|
9
|
|
Six Months to Twelve Months
NOT COMPLETED
|
1
|
1
|
Reasons for withdrawal
| Measure |
Rituximab
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Baseline to Six Months
Withdrawal by Subject
|
0
|
1
|
|
Baseline to Six Months
Disease Progression
|
1
|
1
|
|
Baseline to Six Months
Adverse Event
|
1
|
0
|
|
Six Months to Twelve Months
Withdrawal by Subject
|
0
|
1
|
|
Six Months to Twelve Months
Disease Progression
|
1
|
0
|
Baseline Characteristics
Trial of Rituximab for Graves' Ophthalmopathy
Baseline characteristics by cohort
| Measure |
Rituximab
n=13 Participants
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 Participants
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
Total
n=25 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
57.6 years
STANDARD_DEVIATION 12.7 • n=99 Participants
|
61.8 years
STANDARD_DEVIATION 11.0 • n=107 Participants
|
58.6 years
STANDARD_DEVIATION 11.8 • n=206 Participants
|
|
Sex: Female, Male
Female
|
9 Participants
n=99 Participants
|
8 Participants
n=107 Participants
|
17 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
4 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
13 participants
n=99 Participants
|
12 participants
n=107 Participants
|
25 participants
n=206 Participants
|
|
Clinical Activity Score
|
4.9 units on a scale
STANDARD_DEVIATION 1.0 • n=99 Participants
|
5.3 units on a scale
STANDARD_DEVIATION 1.0 • n=107 Participants
|
5.1 units on a scale
STANDARD_DEVIATION 1.0 • n=206 Participants
|
PRIMARY outcome
Timeframe: baseline, 6 months after the first infusionPopulation: Sample size was computed based on the expected drop of 2.9 and 1.5 points in the CAS score in rituximab and placebo groups. A sample size of 15 in each group will have 80% power to detect a difference in mean values of 1.4 assuming that the common standard deviation is 1.27 using a two group t-test with a 0.050 two-sided significance level.
The clinical activity score (CAS), for Grave's ophthalmopathy has become a widely accepted tool to assess disease activity and help decide the management of the condition. The CAS, which is based on classical signs of inflammation (pain, redness, and swelling), consists of 7 equally weighted items. The total CAS (as used in this study) may range from 0 to 7. The higher the CAS, the greater degree of inflammation is present. A drop in CAS of 2 or more points suggests an improvement in the inflammatory components of the disease. A CAS ≥3 implies active disease.
Outcome measures
| Measure |
Rituximab
n=13 Participants
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 Participants
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Change in Clinical Activity Score (CAS)
|
-1.2 units on a scale
Standard Deviation 2
|
-1.5 units on a scale
Standard Deviation 1.8
|
SECONDARY outcome
Timeframe: 6 months after first infusion, 12 months after first infusionPopulation: Analysis was intent to treat. The last observation was carried forward from the subjects who dropped out before (or at) 24 weeks.
The failure rate was defined as a composite variable of CAS decrease of \< 2 points or need for additional therapy (excluding cosmetic surgery) for the eye disease.
Outcome measures
| Measure |
Rituximab
n=13 Participants
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 Participants
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Failure Rate
Failure rate at 12 months
|
46 percentage of participants
|
50 percentage of participants
|
|
Failure Rate
Failure rate at 6 months
|
69 percentage of participants
|
75 percentage of participants
|
SECONDARY outcome
Timeframe: baseline, 6 months after first infusionPopulation: Intention to treat analysis
Disease severity was measured by the NOSPECS Score. This classification scheme of the eye changes in thyroid eye disease was introduced by the American Thyroid Association. It separates patients into seven classes of disease (class 0-6), with 0 being no signs or symptoms and 6 being sight loss. (The acronym is based on the first letter of the defining characteristic of each class, the classification is known as: 'no signs or symptoms; only signs; soft tissue; proptosis; extraocular muscle; cornea; sight loss' (NOSPECS) ).
Outcome measures
| Measure |
Rituximab
n=13 Participants
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 Participants
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Change in Disease Severity
Improvement by 1 class
|
6 participants
|
8 participants
|
|
Change in Disease Severity
Improvement by 2 classes
|
2 participants
|
2 participants
|
|
Change in Disease Severity
Deterioration
|
2 participants
|
0 participants
|
|
Change in Disease Severity
No change
|
3 participants
|
2 participants
|
SECONDARY outcome
Timeframe: baseline, 12 months after first infusionEye proptosis is a condition resulting in forward displacement of the globe from its normal position within the orbit. It is measured by computed tomography. Improvement in proptosis was defined as a decrease in proptosis by ≥2 mm.
Outcome measures
| Measure |
Rituximab
n=13 Participants
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 Participants
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Change in Proptosis
Proptosis right eye
|
0.82 mm
Standard Deviation 1.4
|
0.80 mm
Standard Deviation 1.3
|
|
Change in Proptosis
Proptosis left eye
|
0.1 mm
Standard Deviation 1.2
|
0.0 mm
Standard Deviation 1.8
|
SECONDARY outcome
Timeframe: baseline, 6 months after first infusionPopulation: Intention to treat analysis
The palpebral fissure is the elliptic space between the medial and lateral canthi of the two open eye lids. In adults, this measures about 10mm vertically and 30mm horizontally. The fissure may be increased in vertical height in Graves' disease. Improvement was defined as a decrease in lid aperture width by ≥3 mm.
Outcome measures
| Measure |
Rituximab
n=13 Participants
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 Participants
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Change in Lid Fissure
Lid fissure right eye
|
0 mm
Interval -1.0 to 1.0
|
0 mm
Interval -1.0 to 1.0
|
|
Change in Lid Fissure
Lid fissure left eye
|
0 mm
Interval -1.5 to 1.0
|
0.5 mm
Interval -1.0 to 1.75
|
SECONDARY outcome
Timeframe: baseline, 6 months after first infusion, 12 months after first infusionPopulation: Intention to treat analysis
Change extraocular motility was assessed using the Gorman diplopia score. Diplopia, commonly known as double vision, is the simultaneous perception of two images of a single object that may be displaced horizontally, vertically, or diagonally (i.e., both vertically and horizontally) in relation to each other. It is usually the result of impaired function of the extraocular muscles, where both eyes are still functional but they cannot converge to target the desired object. The Gorman diplopia score includes four categories: 1) no diplopia (absent), 2) diplopia when the patient is tired or awakening (intermittent), 3) diplopia at extremes of gaze (inconstant), and 4) continuous diplopia in the primary or reading position (constant).
Outcome measures
| Measure |
Rituximab
n=13 Participants
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 Participants
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Change in Extraocular Motility
Change baseline-6 months
|
3 units on a scale
Interval 2.0 to 3.5
|
2.5 units on a scale
Interval 0.0 to 4.0
|
|
Change in Extraocular Motility
Change baseline-12 months
|
2 units on a scale
Interval 0.75 to 3.25
|
1.5 units on a scale
Interval 0.75 to 3.0
|
SECONDARY outcome
Timeframe: baseline, 6 months after first infusion, 12 months after first infusionQuality of life (QoL) was measured by the SF-12 questionnaire. The SF-12 is a multipurpose short form survey with 12 questions, all selected from the SF-36 Health Survey. Physical and Mental Health Composite Scores are computed (combined, scored, and weighted) using the scores of the 12 questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. Improvement was defined as a change of ≥ 6 points.
Outcome measures
| Measure |
Rituximab
n=13 Participants
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 Participants
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Graves' Ophthalmopathy Quality of Life Score Using the Short Form-12 (SF-12) Health Survey
Baseline QoL physical
|
53.2 units on a scale
Interval 42.1 to 56.7
|
39.9 units on a scale
Interval 33.5 to 48.8
|
|
Graves' Ophthalmopathy Quality of Life Score Using the Short Form-12 (SF-12) Health Survey
Baseline QoL mental
|
44.3 units on a scale
Interval 32.8 to 50.7
|
46.1 units on a scale
Interval 36.0 to 51.3
|
|
Graves' Ophthalmopathy Quality of Life Score Using the Short Form-12 (SF-12) Health Survey
6 months QoL mental
|
52.8 units on a scale
Interval 36.1 to 56.7
|
46.1 units on a scale
Interval 35.4 to 57.4
|
|
Graves' Ophthalmopathy Quality of Life Score Using the Short Form-12 (SF-12) Health Survey
6 months QoL physical
|
45.9 units on a scale
Interval 43.6 to 50.8
|
40.3 units on a scale
Interval 38.5 to 52.1
|
|
Graves' Ophthalmopathy Quality of Life Score Using the Short Form-12 (SF-12) Health Survey
12 months QoL physical
|
51.8 units on a scale
Interval 49.8 to 55.5
|
46.7 units on a scale
Interval 41.1 to 53.6
|
|
Graves' Ophthalmopathy Quality of Life Score Using the Short Form-12 (SF-12) Health Survey
12 months QoL mental
|
56.1 units on a scale
Interval 42.8 to 57.8
|
49.4 units on a scale
Interval 35.4 to 56.1
|
SECONDARY outcome
Timeframe: one yearPopulation: Analysis was intent to treat. The last observation was carried forward from the subjects who dropped out before (or at) 52 weeks.
The failure rate was defined as a composite variable of CAS decrease of \< 2 points or need for additional therapy (excluding cosmetic surgery) for the eye disease.
Outcome measures
| Measure |
Rituximab
n=13 Participants
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 Participants
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Failure Rate at One Year
|
46 percentage of participants
|
50 percentage of participants
|
Adverse Events
Rituximab
Placebo
Serious adverse events
| Measure |
Rituximab
n=13 participants at risk
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 participants at risk
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Eye disorders
Dysthroid optic neuropathy
|
15.4%
2/13 • Number of events 2 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
Other adverse events
| Measure |
Rituximab
n=13 participants at risk
Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Rituximab: Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
Methylprednisolone: Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
|
Placebo
n=12 participants at risk
Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV. All subjects will be treated with an acetaminophen tablet and a diphenhydramine hydrochloride tablet before the infusion.
Saline: Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
|
|---|---|---|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/13 • Participants were followed for adverse events for one year after the first infusion.
|
16.7%
2/12 • Number of events 2 • Participants were followed for adverse events for one year after the first infusion.
|
|
Skin and subcutaneous tissue disorders
Rash on face
|
7.7%
1/13 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
|
Respiratory, thoracic and mediastinal disorders
Acute Bronchitis
|
7.7%
1/13 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
|
Blood and lymphatic system disorders
Vasculitis legs
|
7.7%
1/13 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
|
Eye disorders
Significant eye tearing
|
7.7%
1/13 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
|
Gastrointestinal disorders
Tongue pain
|
7.7%
1/13 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
|
Gastrointestinal disorders
Indigestion
|
7.7%
1/13 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
|
Musculoskeletal and connective tissue disorders
Arthritis of left hip
|
7.7%
1/13 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
|
Skin and subcutaneous tissue disorders
Itching of face and scalp
|
7.7%
1/13 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia both knees
|
7.7%
1/13 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
0.00%
0/12 • Participants were followed for adverse events for one year after the first infusion.
|
|
Gastrointestinal disorders
Abdominal Discomfort
|
0.00%
0/13 • Participants were followed for adverse events for one year after the first infusion.
|
8.3%
1/12 • Number of events 2 • Participants were followed for adverse events for one year after the first infusion.
|
|
Gastrointestinal disorders
Diarrhea
|
0.00%
0/13 • Participants were followed for adverse events for one year after the first infusion.
|
8.3%
1/12 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
|
Infections and infestations
Left eye conjunctivitis
|
0.00%
0/13 • Participants were followed for adverse events for one year after the first infusion.
|
8.3%
1/12 • Number of events 1 • Participants were followed for adverse events for one year after the first infusion.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place